JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Metjian, A.
Right arrow Articles by Abrams, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metjian, A.
Right arrow Articles by Abrams, C. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 39, 27943-27947, September 24, 1999


Agonists Cause Nuclear Translocation of Phosphatidylinositol 3-Kinase gamma
A Gbeta gamma -DEPENDENT PATHWAY THAT REQUIRES THE p110gamma AMINO TERMINUS*

Ara Metjian, Richard L. Roll, Alice D. MaDagger , and Charles S. Abrams§

From the Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES

In hematopoietic cells, the signals initiated by activation of the phosphoinositide 3-kinase (PI3K) family have been implicated in cell proliferation and survival, membrane and cytoskeletal reorganization, chemotaxis, and the neutrophil respiratory burst. Of the four isoforms of human PI3K that phosphorylate phosphatidylinositol 4,5-bisphosphate, only p110gamma (or PI3Kgamma ) is associated with the regulatory subunit, p101, and is stimulated by G protein beta gamma heterodimers. We performed immunolocalization of transfected p110gamma in HepG2 cells and found that, under resting conditions, p110gamma was present in a diffuse cytoplasmic pattern, but translocated to the cell nucleus after serum stimulation. Serum-stimulated p110gamma translocation was inhibited by pertussis toxin and could also be induced by overexpression of Gbeta gamma in the absence of serum. In addition, we found that deletion of the amino-terminal 33 residues of p110gamma had no effect on association with p101 or on its agonist-regulated translocation, but truncation of the amino-terminal 82 residues yielded a p110gamma variant that did not associate with p101 and was constitutively localized in the nucleus. This finding implies that the intracellular localization of p110gamma is regulated by p101 as well as Gbeta gamma . The effect of PI3Kgamma in the nucleus is an area of active investigation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES

Phosphoinositide 3-kinases are a group of enzymes that phosphorylate the D-3 position of the inositol ring of phosphatidylinositol to produce phosphatidylinositol 3-phosphate (PI1-3-P), PI-3,4-P2, and PI-3,4,5-P3. After stimulation by growth factor- or G protein coupled-receptors, there is a transient increase in PI-3,4-P2 and PI-3,4,5-P3 (1). The relatively larger pool of PI-3-P remains stable. Much of what is known about the role of PI3K in blood cells derives from the overexpression of PI3K mutants and the use of pharmacologic inhibitors such as wortmannin and LY294002. Studies have suggested that PI3K is involved in several aspects of signaling in hematopoietic cells: 1) cell proliferation, 2) chemotaxis, 3) histamine release from basophils, 3) phagocytosis by monocytes, 4) platelet aggregation, and 5) the respiratory burst of neutrophils (2).

The four isoforms of human PI3K that phosphorylate PI, PI-4-P, and PI-4,5-P2 are classified by their catalytic subunits: p110alpha , p110beta , p110gamma , and p110delta . The most studied human PI3K is a heterodimer composed of p110alpha , p110beta , or p110delta coupled to an adapter protein, p85. These p85-associated PI3K isoforms are tightly linked to signaling mediated by growth factor receptors. After stimulation by extracellular growth factors, the cytoplasmic tail of the growth factor receptor autophosphorylates, enabling it to associate with numerous signaling proteins, including p85, via its two SH2 domains. This recruits p110alpha to the cellular membrane, which appears to be sufficient to activate its lipid kinase activity (3). The binding of activated Ras to p110alpha also appears capable of activating p85-p110, but whether this enhances its membrane association is currently unknown (4). Intracellular localization studies have shown that p85-p110 is present in the cytoplasm with a small component at the extracellular membrane (3); yet two studies using PC12 or human embryonic kidney 293 cells have suggested that p85-associated PI3K can translocate to the nucleus after neuronal growth factor stimulation (5) or H2O2 exposure (6). However, these observations remain controversial.

Several years ago, it was shown that hematopoietic cells possess a PI3K that can be directly stimulated by Gbeta gamma heterodimers (26). Several groups have demonstrated that this G protein-activated PI3K is a heterodimer composed of a catalytic subunit, p110gamma , and an adapter protein, p101 (7, 8). In addition to blood cells, Northern blot analysis demonstrated that p110gamma mRNA is also abundant in skeletal and cardiac muscle, liver, and pancreas (9). This PI3K plays a role in the activation of mitogen-activated protein kinase by G protein-coupled receptors and Btk (10, 11). In reconstitution assays, the p101-p110gamma complex was inhibited by the pleckstrin homology domain-containing protein pleckstrin, whereas the p85-p110 complexes were unaffected (12).

The literature suggests that the regulation of p110alpha /beta /delta catalytic subunits is controlled by their intracellular localization, which, in turn, is controlled by their p85-binding partners. In addition, several reports now provide evidence that p85-associated PI3K can translocate to the cell nucleus (5, 6). However, no published reports specifically address the intracellular localization of p101-p110gamma . Therefore, in this study, we determined, first, the intracellular localization of p110gamma and, second, whether the localization is influenced by binding to p101. Our results show that p110gamma , upon serum stimulation, translocates to the cell nucleus. This serum-induced nuclear translocation is pertussis toxin-sensitive and can be mimicked by overexpression of Gbeta gamma heterodimers, but does not appear to be cell cycle-regulated. However, the nuclear localization is regulated by p101 since the Delta 1-82 truncation variant of p110gamma , which cannot associate with p101, is constitutively localized in the nucleus.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES

Mammalian Expression Vectors-- The cDNA clone of human p110gamma was described previously (13). The p110gamma variants were generated by polymerase chain reaction mutagenesis using the techniques of Ho et al. (14) and Landt et al. (15). The deletion variants, p110gamma (Delta 1-34) and p110gamma (Delta 1-82), also contained the 5'-untranslated region from beta -hemoglobin fused upstream of the initiator methionine. All of these cDNAs were cloned into pCMV5 and contain a carboxyl-terminal additional 9-amino acid hemagglutinin (HA) epitope tag (YPYDVPDYA) recognized by the monoclonal antibody 12CA5. The GFP-p110gamma fusion-expressing plasmid contained the sequence for GFP in place of the stop codon and was generated by the technique of polymerase chain reaction splice overlap extension and cloned into pcDNA3.1+ (Invitrogen, Carlsbad, CA). The sequences of all clones were fully confirmed. The plasmids that direct the expression of an EE epitope (EEEEYMPME)-tagged variant of p101 and Myc epitope (EQKLISEEDL)-tagged bovine p110gamma were a generous gift from Dr. Len Stephens (Babraham Institute, Cambridge, United Kingdom). Plasmids that direct the synthesis of Gbeta 1 and Ggamma 2 were a generous gift from Dr. Janet Robishaw (Geisinger Institute, Danville, PA).

Co-immunoprecipitation Studies-- COS-7SH cells were transfected by the calcium phosphate technique as described previously (16) using plasmids that direct the synthesis of HA-p110gamma variants, with and without EE-p101 or Gbeta gamma . Forty-eight hours later, the cells were washed with phosphate-buffered saline and then lysed on ice in 1 ml of 1% Triton X-100, 0.14 M NaCl, 1 mM MgCl2, 1 mM EGTA, 20 mM HEPES (pH 7.4), 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, and 0.1% aprotinin. After clarification at 13,000 × g for 30 min, the supernatant was incubated with Sepharose G coupled to an anti-EE antibody (BAbCO, Berkeley, CA) overnight. The beads and associated proteins were pelleted at 2000 × g for 30 s, washed extensively in the lysis buffer, and boiled in Laemmli loading buffer. The anti-EE immunoprecipitates were then fractionated by 7.5% SDS-polyacrylamide gel electrophoresis and immunoblotted with the anti-HA antibody HA.11 (BAbCO) to detect the co-immunoprecipitation of HA-p110gamma variants along with EE-p101.

Indirect Immunofluorescence-- HepG2 cells were transiently transfected by the calcium phosphate technique and stained as described previously (17). Platelet-derived growth factor-transformed porcine aortic endothelial (PAE) cells were electroporated as described previously (18). Staining of cells with ethidium monoazide (Molecular Probes, Inc., Eugene, OR) was performed following the manufacturer's protocol.

Microinjection-- Microinjection was performed using an Eppendorf 5171 Micromanipulator with an Eppendorf 5246 Transjector. Plasmid DNA was diluted in 2× injection buffer (100 mM HEPES (pH 7.2), 200 mM KCl, and 10 mM NaPO4) to a final concentration of 25 ng/µl. Transjector settings were injection pressure = 60 hectopascals, compensatory pressure = 20 hectopascals, and time of injection = 0.1 s. Cells were incubated for 6 h following injection and were then fixed in 10% neutral buffered Formalin for 30 min prior to image analysis. Two methods were used for image collection and analysis. Conventional fluorescence microscopy was performed using a Nikon Microphot-SA microscope and camera. We also used the resources of the University of Pennsylvania Cancer Center Confocal Microscopy Core Facility. Confocal images were acquired from a TCS 4D upright microscope and processed on an IBM OS9 workstation using Scanware software. All light microscopic figures were shot at ×40 magnification.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES

p110gamma Translocates to the Cell Nucleus of HepG2 Cells after Serum Stimulation-- To begin to understand the role of PI3Kgamma in vivo, we performed indirect immunofluorescence of transfected p110gamma in human HepG2 hepatoma cells. Liver cells naturally express PI3Kgamma ; therefore, we reasoned that HepG2 cells should contain any accessory proteins needed for proper p101-p110gamma signaling. Since all available antibodies were unable to detect endogenous p110gamma by immunofluorescence, we expressed the HA epitope-tagged p110gamma that was recognized by the anti-HA monoclonal antibody 12CA5. Twenty-four hours after transfection, the cells were placed in medium without serum for 16 h. The cells were then washed, fixed, and stained with an anti-HA antibody.

As shown in Fig. 1 (A and B), when HepG2 cells were transfected with epitope-tagged p110gamma and analyzed under serum-deprived conditions, the cells appeared large and flat. Under these resting conditions, indirect immunofluorescence showed that p110gamma was present in a diffuse cytoplasmic pattern. In contrast, after stimulation of the cells with serum, immunolocalization of p110gamma revealed that it was no longer detected in the cytoplasm, but was found almost exclusively in the nucleus (Fig. 1, C and D). Confocal microscopy verified this finding and revealed that the transported PI3Kgamma was diffusely present throughout the nucleus, but most concentrated at the nuclear membrane. Moreover, PI3Kgamma staining did not coincide with simultaneous staining of the Golgi apparatus with the antibody G2404, a monoclonal antibody directed against the Golgi 58-kDa protein (data not shown). As has been reported previously, overexpression of PI3K did induce morphologic changes, including shrinking of the cytoplasm and ruffling of the cell membrane (5). Although cells overexpressing this protein had dramatic changes in their appearance, they were still viable. This was demonstrated by the exclusion of the DNA-staining agent ethidium monoazide in the absence of cell permeabilization. In addition, the cells did not show any evidence of apoptosis by the terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling immunofluorescence assay. Therefore, in response to serum stimulation, overexpressed p110gamma induces dramatic morphologic changes and translocates to the nucleus.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of serum, Gbeta gamma , and pertussis toxin on the nuclear translocation of p110gamma . HepG2 cells were transiently transfected with HA epitope-tagged p110gamma with or without Gbeta gamma . Twenty-four hours after transfection, the cells were placed in medium containing the supplements indicated below. After growing on coverslips overnight, the cells were fixed and stained with anti-HA antibody (12CA5). The top row are indirect immunofluorescence images, and the bottom row are phase images. The tips of the arrows are placed at the edge of the cytoplasmic membrane for each paired set. A and B, cells were grown overnight in serum-depleted medium. The p110gamma protein was present in a diffuse cytoplasmic pattern, with no p110gamma visualized in the central dark nucleus. C and D, cells grown in 10% serum overnight demonstrated that p110gamma was exclusively localized in the nucleus. E and F, cells were grown in 10% serum with 200 ng/ml pertussis toxin overnight. Pertussis toxin prevented the usual translocation of p110gamma to the nucleus after serum stimulation. G and H, cells were transfected with p110gamma and Gbeta gamma and then incubated with serum plus pertussis toxin. Pertussis toxin did not prevent the nuclear translocation of p110gamma initiated by overexpressed Gbeta gamma heterodimers.

Overexpression of p101, which is endogenously present in HepG2 cells, had no influence on p110gamma nuclear translocation and, under either resting or stimulated conditions, was present in both the cytoplasm and nucleus (data not shown). We performed time course experiments to determine how rapidly after cell stimulation p110gamma migrates to the nucleus. In these experiments, cells were transfected with plasmids encoding PI3Kgamma . Twenty-four hours later, the cells were serum-deprived for an additional 16 h. At this point, all of the PI3Kgamma protein was cytoplasmic. The medium was then changed to Dulbecco's modified Eagle's medium containing 10% fetal calf serum, and the time course of nuclear translocation was measured using the addition of serum as the defined time 0. These experiments showed that the translocation of p110gamma began as rapidly as 2 h after serum exposure and was almost complete by 7 h, but maximal after ~12 h. This time period is similar to the nuclear translocation seen with p110alpha in PC12 cells after stimulation with neuronal growth factor (5).

We next sought to determine whether G protein-coupled or growth factor receptor-mediated signaling pathways were responsible for the serum-induced nuclear translocation of p110gamma . To examine this issue, we preincubated cells with pertussis toxin to inhibit the release of Gbeta gamma heterodimers from Galpha i-coupled receptors. Cells were then examined in the presence or absence of serum stimulation. In the absence of serum, pertussis toxin did not affect the diffuse cytoplasmic distribution of p110gamma in serum-starved cells (data not shown). However, pertussis-toxin inhibited the serum-induced p110gamma nuclear translocation (Fig. 1, E and F). This suggests that the serum-induced nuclear translocation of PI3Kgamma is dependent on a Gbeta gamma -mediated signaling pathway. To test this hypothesis, we attempted to mimic serum-mediated nuclear translocation by overexpression of Gbeta gamma heterodimers. The overexpression of Gbeta gamma heterodimers resulted in the nuclear translocation of p101 even in the absence of serum stimulation (data not shown). As expected, pertussis toxin failed to alter the nuclear localization of p110gamma induced by overexpression of Gbeta gamma heterodimers (Fig. 1, G and H). Together, these observations suggest that serum contains a factor that initiates the nuclear translocation of p110gamma by causing release of Gbeta gamma heterodimers downstream from a Galpha i-coupled receptor.

To confirm this Gbeta gamma -mediated translocation of p110gamma , a plasmid directing the expression of a chimeric protein composed of GFP fused to the carboxy terminus of p110gamma was microinjected into HepG2 cells. Cells were analyzed 6 h after microinjection of the plasmid under serum-starved conditions. Similar to our observations with indirect immunofluorescence, under resting conditions, the GFP-p110gamma fusion protein was found in a diffuse cytoplasmic pattern (Fig. 2, A and C). In contrast, when plasmids that direct the expression of Gbeta gamma heterodimers were simultaneously microinjected with the GFP-p110gamma plasmid, the GFP fusion protein was exclusively localized in the nucleus (Fig. 2, B and D). Thus, in these cells, which endogenously express PI3Kgamma , there is a Gbeta gamma -mediated transport of this lipid kinase from the cytoplasm to the nucleus.


View larger version (114K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of Gbeta gamma on the nuclear translocation of GFP-p110gamma . Serum-starved HepG2 cells were microinjected with plasmids directing the expression of GFP-p110gamma with or without Gbeta gamma . Six hours after microinjection, the cells were fixed and visualized by direct fluorescence images in A and B and phase plus immunofluorescence images in C and D. A and C, cells microinjected with GFP-p110gamma alone. The p110gamma protein was present in a diffuse cytoplasmic pattern, with no p110gamma visualized in the central dark nucleus. B and D, cells transfected with GFP-p110gamma and Gbeta gamma . Similar to the immunofluorescence studies shown in Fig. 1, the presence of Gbeta gamma contributed to the translocation of GFP-p110gamma to the cell nucleus.

We questioned whether cell lines derived from tissues that do not endogenously contain PI3Kgamma also contain the necessary accessory proteins for PI3Kgamma nuclear translocation. As shown in Fig. 3A, when p101 and p110gamma were transfected into stably platelet-derived growth factor-expressing PAE cells, staining for p110gamma demonstrated that it was found in both the cytoplasm and nucleus. In these platelet-derived growth factor-overexpressing cells, this pattern of distribution was independent of serum (data not shown). As shown in Fig. 3 (B and C), the intracellular localization was also independent of cell cycle as demonstrated by thymidine block (arresting cells at the G1/S boundary) or by thymidine block and release (arresting cells in S phase). In contrast, transfection of p101 and p110gamma into COS-7SH cells demonstrated an exclusively cytoplasmic distribution for p110gamma (data not shown). Together, this suggests that, like p101 and p110gamma , the accessory proteins required for p110gamma nuclear translocation are not ubiquitously expressed.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of cell cycle on the intracellular localization of p110gamma in PAE cells. Serum-starved PAE cells were electroporated. Plasmids directing the expression of p101 and p110gamma and the cells were analyzed after thymidine block and release. Cells were analyzed after 48 h of 10% serum stimulation alone (A) or following thymidine block to arrest cells at G1/S (B) or following thymidine block and release to S phase arrest (C).

Studies of the Interaction between p110gamma and p101-- There is some controversy in the literature regarding the necessity of the p101 subunit for p110gamma function (7, 9, 10). We next sought to determine the role of p101 in the nuclear translocation of p110gamma by examining the intracellular localization of a p110gamma mutant unable to associate with p101. Since the interaction between p85 and p110alpha involves the amino terminus of p110alpha , we first tested whether p110gamma variants lacking the amino terminus could associate with p101. To perform these experiments, we used a plasmid directing the expression of an EE epitope (EEEEYMPME)-tagged variant of p101, which allowed the immunoprecipitation of p101 along with its associated proteins with an anti-EE antibody. Full-length p110gamma or deletion variants of p110gamma were coexpressed with EE-p101 in COS-7SH cells. After lysis, p101 and its associated proteins were immunoprecipitated with an anti-EE antibody, fractionated by SDS-polyacrylamide gel electrophoresis, and immunoblotted with an anti-HA antibody. The anti-HA antibody recognizes the epitope added to all of the p110gamma variants. As shown in Fig. 4 (left panel), all of the variants coexpressed well with p101. In addition, full-length p110gamma (wild type (WT)) and the 34-amino acid deletion variant (p110gamma (Delta 1-34)) both immunoprecipitated efficiently with p101 (Fig. 4, right panel). However, the variant that was missing the first 82 amino-terminal residues completely failed to immunoprecipitate with p101. This implies that a region of p110gamma critical for association with p101 is located between residues 35 and 82 in p110gamma .


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 4.   Residues 1-82 in p110gamma are required for interaction with p101. COS-7SH cells were transfected with HA epitope-tagged p110gamma variants and EE epitope-tagged p101. Cells were lysed and immunoblotted with the anti-HA antibody 12CA5. As shown on the immunoblot of the total cell lysates, all three p110gamma variants were expressed approximately equally, but only the wild type (WT) and Delta 1-34 variant could co-immunoprecipitate with p101. This implies that the interaction for p101 requires residues 35 through 82.

Having identified a p110gamma variant that did not associate with p101, we next tested whether this mutant translocated toward the nucleus in a fashion similar to wild-type p110gamma . In contrast to the wild-type protein, p110gamma (Delta 1-82) was found in the nucleus even in the absence of serum (Fig. 5, A and B). Overexpression of Gbeta gamma heterodimers had no apparent influence on its intracellular localization (data not shown). This implies that p101 plays a role in the regulation of the intracellular localization of p110gamma by retaining it in the cytoplasm in the absence of signals that initiate nuclear translocation. Consistent with this hypothesis, the p110gamma -(Delta 1-34) deletion variant, which does associate with p101, translocated from the cytoplasm to the nucleus in an agonist-stimulated fashion similar to the wild-type protein (data not shown).


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 5.   Intracellular localization of p110gamma (Delta 1-82). HepG2 cells were transiently transfected with HA epitope-tagged p110gamma (Delta 1-82) and analyzed by immunofluorescence with the 12CA5 antibody after 16 h of serum deprivation. Shown are the indirect (A) and phase plus (B) immunofluorescence images of two transfected cells. Deletion of the first 82 residues from p110gamma induced it to localize in the cell nucleus in serum-deprived cells. This distribution is in contrast to the diffuse cytoplasmic localization of full-length p110gamma in serum-starved cells (see Fig. 1, A and B).


    CONCLUSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES

Although PI3Kgamma has been well described as a mediator of signaling events at the plasma membrane, this work suggests that PI3Kgamma may also play a role at the nuclear membrane. Specifically, we have shown that factors present in serum cause p110gamma to move to the nucleus in transfected HepG2 cells. This response to serum can be inhibited by pertussis toxin and can be mimicked by overexpression of Gbeta gamma heterodimers. A mutant form of p110gamma that is unable to bind to p101 is constitutively localized in the nucleus.

These observations raise a number of issues, including the mechanism by which PI3Kgamma is transported to the nucleus, the impact of PI3Kgamma on nuclear signaling, and whether these findings also apply to growth factor-activated p85-p110alpha /beta . The mechanism by which PI3Kgamma is translocated to the nucleus at this point is unclear. This process certainly can be regulated by the release of Gbeta gamma heterodimers. Our studies suggest that p101 appears to regulate this translocation since a variant of p110gamma that does not associate with p101 is constitutively found in the nucleus. This is similar to the mechanism by which mitogen-activated protein kinase shuttles between the nucleus and the cytoplasm by alternatively interacting with cytoplasmic and nuclear retention (or anchoring) proteins (20). This model would imply sequences for nuclear import and retention, the existance and perhaps sequences for nuclear export and cytoplasmic retention within p110gamma . Examination of the p110gamma sequence reveals two potential nuclear import signals: R17RRRR and K806KKP. Since the p110gamma -(Delta 1-34) variant is capable of nuclear translocation, it implies that R17RRRR is not critical. Whether K806KKP is required for nuclear transport is currently unknown, as is the role of second messenger formation.

The effect of PI3K on mitosis and survival is a topic of recent interest. Evidence derived from the use of inhibitors (or overexpressed effectors) of PI3K implies that a tight regulation of PI3K is critical for both cell growth and cell death. Most likely, this effect of PI3K is the result of an increase in lipid second messengers. Although cytoplasmic p101-p110gamma will phosphorylate PI, PI-4-P, and PI-4,5-P2, only cytoplasmic PI-3,4-P2 and PI-3,4,5-P3 appear to change significantly after G protein-coupled receptor stimulation. Nuclear membranes, which probably contain the substrate for nuclear lipid kinases, contain abundant quantities of PI, PI-4-P, and PI-4,5-P2. But at this point, the substrate for PI3Kgamma in the nucleus remains to be determined. It has long been appreciated that individual phospholipid concentrations vary with the cell cycle. For example, Dobos et al. (21) demonstrated that PI-3-P is elevated during the G2/M phase of the cell cycle. Recently, it has also been suggested that the cell cycle may actually be influenced by phospholipid content (22-24). Consistent with this hypothesis, fibroblasts deprived of choline and synchronized in G1 phase by serum starvation do not efficiently enter S phase after serum stimulation (25). This implies that phospholipid synthesis is required for S phase entry. It is possible that nuclear PI3Kgamma influences the cell cycle by transiently elevating the PI-3-P concentration. Recent evidence suggests that p110gamma may also have protein kinase activity (19). This raises the alternative possibility that the substrate for nuclear PI3Kgamma is a protein, instead of a lipid.

Although most reports in the literature show a cytoplasmic (or plasma membrane) intracellular distribution for p85, two reports have suggested that it may relocate to the nucleus after neuronal growth factor or H2O2 stimulation (5, 6). Consistent with this observation, preliminary studies in our laboratory have demonstrated that hemagglutinin epitope-tagged p110alpha expressed in HepG2 cells will also translocate to the nuclear membrane after serum stimulation.2 This implies that the observations of this report will extend to signaling initiated by growth factor as well as G protein-coupled receptors.

    ACKNOWLEDGEMENTS

We thank Drs. Heidi Welsh, Phillip Hawkins, and Len Stephens for work with the PAE cells and Drs. Joel S. Bennett and Lawrence F. Brass (University of Pennsylvania) for helpful comments on the manuscript.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants HL40378 and HL54500.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Dept. of Medicine, University of North Carolina Medical School, Chapel Hill, North Carolina 27514.

§ To whom correspondence should be addressed: Hematology-Oncology Div., Biomedical Research Bldg. II/III, Rm. 912, University of Pennsylvania, 421 Curie Blvd., Philadelphia, PA 19104. Tel.: 215-898-1058; Fax: 215-573-7400; E-mail: abramsc@mail.med.upenn.edu.

2 A. Metjian and C. S. Abrams, unpublished observation.

    ABBREVIATIONS

The abbreviations used are: PI, phosphatidylinositol; PI3K, phosphatidylinositol 3-kinase; HA, hemagglutinin; GFP, green fluorescent protein; PAE, porcine aortic endothelial.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES

1. Stephens, L. R., Jackson, T. R., and Hawkins, P. T. (1993) Biochim. Biophys. Acta 1179, 27-75[Medline] [Order article via Infotrieve]
2. Nakanishi, S., Yano, H., and Matsuda, Y. (1995) Cell. Signal. 7, 545-557[CrossRef][Medline] [Order article via Infotrieve]
3. Klippel, A., Reinhard, C., Kavanaugh, W. M., Apell, G., Escobedo, M.-A., and Williams, L. T. (1996) Mol. Cell. Biol. 16, 4117-4127[Abstract]
4. Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana, P., Downward, J., and Parker, P. J. (1994) Curr. Biol. 4, 798-806[CrossRef][Medline] [Order article via Infotrieve]
5. Neri, L. M., Milani, D., Bertolaso, L., Stroscio, M., Bertagnolo, V., and Capitani, S. (1994) Cell. Mol. Biol. 40, 619-626[Medline] [Order article via Infotrieve]
6. Tanaka, K., Horiguchi, K., Yoshida, T., Takeda, M., Fujisawa, H., Takeuchi, K., Umeda, M., Kato, S., Ihara, S., Nagata, S., and Fukui, Y. (1999) J. Biol. Chem. 274, 3919-3922[Abstract/Free Full Text]
7. Stephens, L. R., Eguinoa, A., Erdjument-Bromage, H., Lui, M., Cooke, F., Coadwell, J., Smrcka, A. S., Thelen, M., Cadwallader, K., Tempst, P., and Hawkins, P. T. (1997) Cell 89, 105-114[CrossRef][Medline] [Order article via Infotrieve]
8. Tang, X., and Downes, C. P. (1997) J. Biol. Chem. 272, 14193-14199[Abstract/Free Full Text]
9. Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malek, D., Stoyanova, S., Vanhaesebroeck, B., Dhand, R., Nürnberg, B., Gierschik, P., Seedorf, K., Hsuan, J. J., Waterfield, M. D., and Wetzker, R. (1995) Science 269, 690-693[Abstract/Free Full Text]
10. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420[CrossRef][Medline] [Order article via Infotrieve]
11. Li, Z., Wahl, M. I., Eguinoa, A., Stephens, L. R., Hawkins, P. T., and Witte, O. N. (1998) Proc. Natl. Acad. Sci. U. S. A. 94, 13820-13825[Abstract/Free Full Text]
12. Abrams, C. S., Zhang, J., Downes, C. P., Tang, X., Zhao, W., and Rittenhouse, S. E. (1996) J. Biol. Chem. 271, 25192-25197[Abstract/Free Full Text]
13. Ma, A. D., Metjian, A., Bagrodia, S., Taylor, S., and Abrams, C. S. (1998) Mol. Cell. Biol. 18, 4744-4751[Abstract/Free Full Text]
14. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59[CrossRef][Medline] [Order article via Infotrieve]
15. Landt, O., Grunert, H.-P., and Hahn, U. (1990) Gene (Amst.) 96, 125-128[CrossRef][Medline] [Order article via Infotrieve]
16. Morris, J. F., Madden, S. L., Tournay, O. E., Cook, D. M., Sukatme, V. P., and Rauscher, F. J. (1991) Oncogene 6, 2339-2348[Medline] [Order article via Infotrieve]
17. Ma, A. D., Brass, L. F., and Abrams, C. S. (1997) J. Cell Biol. 136, 1071-1079[Abstract/Free Full Text]
18. Hawkins, P. T., Eguinoa, A., Qui, R.-G., Stokoe, D., Cooke, F. T., Walters, R., Wennstrom, S., Claesson-Welsh, L., Evans, T., Symons, M., and Stephens, L. (1995) Curr. Biol. 5, 393-403[CrossRef][Medline] [Order article via Infotrieve]
19. Bondeva, T., Pirola, L., Bulgarelli-Leva, G., Rubio, I., Wetzker, R., and Wymann, M. P. (1998) Science 282, 293-296[Abstract/Free Full Text]
20. Lenormand, P., Brondello, J. M., Brunet, A., and Pouyssegur, J. (1998) J. Cell Biol. 142, 625-633[Abstract/Free Full Text]
21. Dobos, G. J., Wu, X. R., and Traynor-Kaplan, A. (1993) FEBS Lett. 324, 143-146[CrossRef][Medline] [Order article via Infotrieve]
22. Manzoli, L., Gilmour, R. S., Martelli, A. M., Billi, A. M., and Cocco, L. (1996) Anticancer Res. 16, 3283-3286[Medline] [Order article via Infotrieve]
23. Jackowski, S. (1996) J. Biol. Chem. 271, 20219-20222[Free Full Text]
24. Klippel, A., Escobedo, M.-A., Wachowicz, M. S., Apell, G., Brown, T. W., Giedlin, M. A., Kavanaugh, W. M., and Williams, L. T. (1998) Mol. Cell. Biol. 18, 5699-5711[Abstract/Free Full Text]
25. Terce, F., Brun, H., and Vance, D. E. (1994) J. Lipid. Res. 35, 2130-2142[Abstract]
26. Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Sternweiss, P. C., and Hawkins, P. T. (1994) Cell 77, 83-93[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
J.-L. Liu, Z. Mao, T. A. LaFortune, M. M. Alonso, G. E. Gallick, J. Fueyo, and W.K. A. Yung
Cell Cycle Dependent Nuclear Export of Phosphatase and Tensin Homologue Tumor Suppressor Is Regulated by the Phosphoinositide-3-Kinase Signaling Cascade
Cancer Res., November 15, 2007; 67(22): 11054 - 11063.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
Y. Lindsay, D. McCoull, L. Davidson, N. R. Leslie, A. Fairservice, A. Gray, J. Lucocq, and C. P. Downes
Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression
J. Cell Sci., December 15, 2006; 119(24): 5160 - 5168.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J.-L. Liu, X. Sheng, Z. K. Hortobagyi, Z. Mao, G. E. Gallick, and W. K. A. Yung
Nuclear PTEN-Mediated Growth Suppression Is Independent of Akt Down-Regulation
Mol. Cell. Biol., July 15, 2005; 25(14): 6211 - 6224.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. W. Ledeen and G. Wu
Nuclear lipids: key signaling effectors in the nervous system and other tissues
J. Lipid Res., January 1, 2004; 45(1): 1 - 8.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Deleris, D. Bacqueville, S. Gayral, L. Carrez, J.-P. Salles, B. Perret, and M. Breton-Douillon
SHIP-2 and PTEN Are Expressed and Active in Vascular Smooth Muscle Cell Nuclei, but Only SHIP-2 Is Associated with Nuclear Speckles
J. Biol. Chem., October 3, 2003; 278(40): 38884 - 38891.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. S. Popova and M. M. Rasenick
G{beta}{gamma} Mediates the Interplay between Tubulin Dimers and Microtubules in the Modulation of Gq Signaling
J. Biol. Chem., September 5, 2003; 278(36): 34299 - 34308.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Y.-S. Bae, J. C. Park, R. He, R. D. Ye, J.-Y. Kwak, P.-G. Suh, and S. Ho Ryu
Differential Signaling of Formyl Peptide Receptor-Like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or Lipoxin A4 in Human Neutrophils
Mol. Pharmacol., September 1, 2003; 64(3): 721 - 730.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
C. Brock, M. Schaefer, H. P. Reusch, C. Czupalla, M. Michalke, K. Spicher, G. Schultz, and B. Nurnberg
Roles of G{beta}{gamma} in membrane recruitment and activation of p110{gamma}/p101 phosphoinositide 3-kinase {gamma}
J. Cell Biol., January 2, 2003; 160(1): 89 - 99.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
R. F. Irvine
Nuclear Lipid Signaling
Sci. Signal., September 17, 2002; 2002(150): re13 - re13.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. A. Didichenko and M. Thelen
Phosphatidylinositol 3-Kinase C2alpha Contains a Nuclear Localization Sequence and Associates with Nuclear Speckles
J. Biol. Chem., December 14, 2001; 276(51): 48135 - 48142.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
V. P. Krymskaya, A. J. Ammit, R. K. Hoffman, A. J. Eszterhas, and R. A. Panettieri Jr.
Activation of class IA PI3K stimulates DNA synthesis in human airway smooth muscle cells
Am J Physiol Lung Cell Mol Physiol, May 1, 2001; 280(5): L1009 - L1018.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. S. Richards
New Signaling Pathways for Hormones and Cyclic Adenosine 3',5'-Monophosphate Action in Endocrine Cells
Mol. Endocrinol., February 1, 2001; 15(2): 209 - 218.
[Abstract] [Full Text]


Home page
Am. J. Pathol.Home page
A. Perren, P. Komminoth, P. Saremaslani, C. Matter, S. Feurer, J. A. Lees, P. U. Heitz, and C. Eng
Mutation and Expression Analyses Reveal Differential Subcellular Compartmentalization of PTEN in Endocrine Pancreatic Tumors Compared to Normal Islet Cells
Am. J. Pathol., October 1, 2000; 157(4): 1097 - 1103.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. V. Naga Prasad, G. Esposito, L. Mao, W. J. Koch, and H. A. Rockman
Gbeta gamma -dependent Phosphoinositide 3-Kinase Activation in Hearts with in Vivo Pressure Overload Hypertrophy
J. Biol. Chem., February 18, 2000; 275(7): 4693 - 4698.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Sindic', A. Aleksandrova, A. P. Fields, S. Volinia, and H. Banfic'
Presence and Activation of Nuclear Phosphoinositide 3-Kinase C2beta during Compensatory Liver Growth
J. Biol. Chem., May 18, 2001; 276(21): 17754 - 17761.
[Abstract] [Full Text] [PDF]


Home page